Pharvaris announced the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for deucrictibant for the on-demand treatment of HAE following review of data from a preplanned interim analysis of the ongoing 26-week nonclinical study. Pharvaris expects to submit data from the 26-week nonclinical study by the end of 2023 to address the remaining hold on the IND application for deucrictibant for prophylactic treatment of HAE.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PHVS:
- Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
- Pharvaris Announces $70 Million Private Placement Financing
- Pharvaris announces $70M private placement
- Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
- Pharvaris Announces Annual Meeting of Shareholders